ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

treprostinil

Also written as “Inhaled Treprostinil”, “treprostinil diethanolamine” and “Oral Treprostinil”.

Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Scleroderma, Systemic · Idiopathic Pulmonary Fibrosis · Chronic Limb-Threatening Ischemia, led by 5 companies.

Drug pageTreprostinil: every studyMany companies study it; this page follows only the 71 they lead. All 99 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 14, 200371 company-led studies, 9 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
United Therapeuticsits history only625 open or runningphase 4since Apr 14, 2003Oct 18, 1999Nov 2027phase 3 · NCT05943535
Liquidia Technologiesits history only64 open or runningphase 4since Aug 7, 2026Jan 3, 2018Feb 2027phase 2 · NCT07748000
Mannkind10 open or runningphase 1since Mar 1, 2018Mar 1, 2018none ahead
Pharmosa Biopharmits history only10 open or runningphase 1since Jul 23, 2019Jul 23, 2019none ahead
SciPharm SàRLits history only10 open or runningphase 3since Aug 12, 2011Aug 12, 2011none ahead

Also a collaborator on its studies: PPD Development, LP, Nuventra, FGK Clinical Research and CVie Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Mannkind only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 1, 2018First study: phase 1 study in Pulmonary Arterial HypertensionFirst studyNCT03464864 · 36 enrolled · United States
  2. Jun 9, 2019Named treprostinilINNProposed as its International Nonproprietary Name in WHO's List 121

TargetBeta

PTGIR →read by rule
“Prostanoid IP receptor agonist; Prostanoid IP receptor agonist; Prostanoid IP receptor agonist”ChEMBL 37, by rule

Other programs on PTGIR

ProgramCompanyFurthest phaseStudies
selexipagruleJohnson & Johnsonphase 423

Studies

The one study Mannkind leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03464864Pulmonary Arterial Hypertension · United States1CompletedJun 5, 201836

How it is read

Names in the registry

  • “Inhaled Treprostinil”, 7 entries
  • “treprostinil diethanolamine”, 6 entries
  • “Oral Treprostinil”, 5 entries
  • “treprostinil sodium”, 5 entries
  • “UT-15C SR”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.